Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients

被引：0
|
作者：
Rogado, J. [1 ]
Romero Laorden, N. [2 ]
Sanchez Torres, J. M. [2 ]
Ramos-Levi, A. [3 ]
Pacheco-Barcia, V. E. [2 ]
Ballesteros Garcia, A. I. [2 ]
Arranz, R. [4 ]
Lorenzo, A. [5 ]
Gullon, P. [6 ]
Garrido, A. [2 ]
Serra, J. M. [7 ]
Donnay, O. [2 ]
Adrados, M. [8 ]
Costas, P. [2 ]
Aspa, J. [9 ]
Alfranca, A. [10 ]
Mondejar, R. [2 ]
Colomer Bosch, R. [2 ]
机构：
[1] HU Infanta Leonor, Hosp Univ La Princesa, Med Oncol, Madrid, Spain
[2] Hosp Univ La Princesa, Med Oncol, Madrid, Spain
[3] Hosp Univ La Princesa, Endocrinol, Madrid, Spain
[4] Hosp Univ La Princesa, Hematol, Madrid, Spain
[5] Hosp Gen Segovia, Hematol, Segovia, Spain
[6] Alcala Univ, Social & Cardiovasc Epidemiol Res Grp, Alcala De Henares, Spain
[7] Hosp Univ La Princesa, Pharm, Madrid, Spain
[8] Hosp Univ La Princesa, Pathol, Madrid, Spain
[9] Hosp Univ La Princesa, Pneumonol, Madrid, Spain
[10] Hosp Univ La Princesa, Immunol, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1287P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
    Rogado, Jacobo
    Romero-Laorden, Nuria
    Miguel Sanchez-Torres, Jose
    Maria Ramos-Levi, Ana
    Pacheco-Barcia, Vilma
    Isabel Ballesteros, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido, Ana
    Serra Lopez-Matencio, Jose Maria
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantzazu
    Mondejar, Rebeca
    Colomer, Ramon
    [J]. ONCOIMMUNOLOGY, 2020, 9 (01):
  • [2] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Bangyou Zuo
    Xiaobo Yang
    Xu Yang
    Jin Bian
    Junyu Long
    Dongxu Wang
    Cong Ning
    Yanyu Wang
    Ziyu Xun
    Yunchao Wang
    Xin Lu
    Yilei Mao
    Xinting Sang
    Haitao Zhao
    [J]. Cancer Immunology, Immunotherapy, 2022, 71 : 1889 - 1896
  • [3] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Zuo, Bangyou
    Yang, Xiaobo
    Yang, Xu
    Bian, Jin
    Long, Junyu
    Wang, Dongxu
    Ning, Cong
    Wang, Yanyu
    Xun, Ziyu
    Wang, Yunchao
    Lu, Xin
    Mao, Yilei
    Sang, Xinting
    Zhao, Haitao
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1889 - 1896
  • [4] Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
    Liu, Qingyan
    Li, Rong
    Li, Lingling
    Wang, Gaokun
    Ji, Shiyu
    Zheng, Xuan
    Jia, Xiaodong
    Tao, Haitao
    Hu, Yi
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [6] Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
    Rai, R.
    McQuade, J. L.
    Wang, D. Y.
    Park, J. J.
    Nahar, K.
    Sosman, J. A.
    Beckermann, K. E.
    Haydu, L. E.
    Lo, S.
    Rubinstein, S.
    Beckermann, K. E.
    McKean, M.
    Matthew, S.
    Guminski, A.
    Carlino, M. S.
    Davies, M.
    Johnson, D. B.
    Long, G. V.
    Menzies, A. M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Yu Jung
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    Lee, Jong Seok
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1312 - S1313
  • [8] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
  • [9] Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
    Rogado, J.
    Sanchez-Torres, J. M.
    Romero-Laorden, N.
    Ballesteros, A., I
    Pacheco-Barcia, V
    Ramos-Levi, A.
    Arranz, R.
    Lorenzo, A.
    Gullon, P.
    Donnay, O.
    Adrados, M.
    Costas, P.
    Aspa, J.
    Alfranca, A.
    Mondejar, R.
    Colomer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 109 : 21 - 27
  • [10] Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
    Sahni, Sakshi
    Valecha, Gautam
    Sahni, Ankit
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2018, 10 (12)
12345